Page 10 - Randomized Trial News Today

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a marketed

Large increases in event-free survival with two CAR T-cell products in second line

ELEVATE-RR head-to-head trial data also presented at ASH showed patients on ibrutinib experienced a 37% higher burden of adverse events of any grade while on treatment vs. patients on CALQUENCE ... | December 12, 2021

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that insights around COVID-19 vaccination rates among people living with HV have been published in the Journal of Infectious Diseases.

COVID-19 vaccination rates differ significantly among people with HIV, researchers found. According to a study published in the Journal of Infectious Diseases, factors that influence these differences include age, race, sex, body mass index and country of residence.

COVID-19 vaccination is especially important for immunocompromised individuals, such as people living with HIV, who face higher risks of developing severe symptoms and dying from COVID-19.

Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi that endangers almost 70 million people worldwide. The only two drugs that are currently approved for its treatment, benznidazole and nifurtimox, have controversial efficacy in adults and restricting safety issues, leaving thousands of patients without a suitable treatment. The neglect of Chagas disease is further illustrated by the lack of a robust and diverse drug discovery and development portfol...

PCI guided by fractional flow reserve assessment may have yielded better outcomes in patients with less complex coronary anatomy, researchers say; others doubt the appropriateness of the subgroup analysis.

November 2, 2021 Philips debuts three new solutions in the North American market that will help drive procedural innovation and workflow efficiency, adding to the company's ecosystem of interventional